Aprea Therapeutics Opens Above IPO Price

Aprea Therapeutics, Inc. APRE made its public debut Thursday morning, opening at $15.46 after being priced at $15 per share.

The shares are listed on the Nasdaq under the ticker symbol “APRE.”

Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53.

JPMorgan, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.

Related Links:

IGM Biosciences Opens Above IPO Price

Ping Identity Holding Opens Above IPO Price